Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tetrabenazine
Drug ID BADD_D02175
Description A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Indications and Usage Treatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
Marketing Status approved; investigational
ATC Code N07XX06
DrugBank ID DB04844
KEGG ID D08575
MeSH ID D013747
PubChem ID 6018
TTD Drug ID D09PJX
NDC Product Code 51224-425; 67386-421; 68180-409; 63827-1013; 65977-0085; 47335-277; 51407-481; 27241-177; 60505-3882; 65085-0064; 27241-176; 47335-179; 69452-117; 70436-102; 43598-395; 60505-3883; 70436-101; 57821-010; 51407-480; 68682-422; 31722-821; 43598-394; 51224-426; 69452-118; 69766-076; 31722-822; 67386-422; 42973-179; 68180-408; 68682-421; 64330-066; 64567-0025; 65015-831
UNII Z9O08YRN8O
Synonyms Tetrabenazine | Nitoman | Xenazine
Chemical Information
Molecular Formula C19H27NO3
CAS Registry Number 718635-93-9
SMILES CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Speech disorder19.19.02.002; 17.02.08.003; 22.12.03.0270.004468%Not Available
Stress19.06.02.0040.001184%Not Available
Suicidal ideation19.12.01.0030.007645%
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.001454%Not Available
Tardive dyskinesia17.01.02.0120.003607%Not Available
Tension19.06.02.005--Not Available
Tic19.11.04.001; 17.02.05.0240.005922%Not Available
Torticollis17.01.03.003; 15.05.04.0030.000538%Not Available
Tremor17.01.06.0020.008560%
Trismus15.05.04.004; 17.01.03.0040.000808%
Unresponsive to stimuli17.02.05.0310.001723%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Vomiting07.01.07.003--
Withdrawal syndrome19.07.06.023; 08.06.02.0120.001184%Not Available
Mental status changes19.07.01.0010.002100%Not Available
Balance disorder17.02.02.007; 08.01.03.0810.001454%Not Available
Bipolar disorder19.16.01.0030.001077%Not Available
Angiopathy24.03.02.007--Not Available
Adverse event08.06.01.0100.007483%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.000808%Not Available
Mental disorder19.07.01.002--Not Available
Abnormal behaviour19.01.01.0010.004361%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.0490.000538%Not Available
Blood disorder01.05.01.004--Not Available
Adverse drug reaction08.06.01.0090.004737%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages